BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a protective protein found naturally in human gastric juice. It is widely used off-label for accelerating the healing of soft tissue injuries (tendons, ligaments, muscle) and treating gastrointestinal disorders, though human clinical evidence remains limited compared to extensive animal data.
Strongest benefit: Accelerating the healing of tendons, ligaments, and muscle tissue in animal models via enhanced angiogenesis (VEGF) and cell migration[^2, ^3, ^4].
Notable effect: Potent cytoprotective effects in the gut, protecting against NSAID-induced ulcers and promoting fistula healing in rodents.
Key limitation: Human clinical trials are scarce; most data comes from rats, with only a few small Phase II trials for inflammatory bowel disease (IBD) and retrospective analyses for joint pain.
Safety concern: Currently listed as a Category 2 substance by the FDA (banned for compounding) due to theoretical immunogenicity and lack of approval; prohibited by WADA for athletes.
What people use it for
Main goals: Repairing sports injuries (tendonitis, tears), healing "leaky gut" and IBD, and reducing recovery time from surgery.
Evidence quality:Promising (Yellow) – Strong mechanistic and animal data, but limited high-quality human randomized controlled trials (RCTs).
FDA status:Unapproved / Category 2. As of late 2023, the FDA placed BPC-157 on the "Category 2 Bulk Drug Substances" list. This effectively bans compounding pharmacies from making BPC-157 products due to concerns over safety, immunogenicity, and lack of proven efficacy. It is not an FDA-approved drug for any indication.
Prescription requirement: Technically requires a prescription if compounded (before the ban), but now largely unavailable through legitimate medical channels in the US. Often sold as a "research chemical" explicitly labeled "not for human consumption."
Sports and competition
WADA status:Prohibited. BPC-157 is listed under section S0 (Non-Approved Substances) of the WADA Prohibited List. It is banned at all times (both in-competition and out-of-competition) for athletes subject to anti-doping testing.
Source quality considerations
Because pharmaceutical-grade BPC-157 is difficult to obtain due to regulatory restrictions, most users rely on gray-market "research chemicals."
These sources often lack third-party purity testing, posing risks of contamination, underdosing, or the presence of heavy metals and endotoxins.
Definition
BPC-157 is a partial sequence (fragment) of a larger protein called "Body Protection Compound" (BPC) that was originally isolated from human gastric juice. It is a synthetic pentadecapeptide consisting of 15 amino acids.
Mechanism vs. Endogenous BPC
Native BPC acts as a cytoprotective factor in the stomach, helping to maintain the integrity of the stomach lining against acid and digestive enzymes. BPC-157 retains these protective properties but appears to be stable in gastric juice (unlike many peptides) and exerts systemic healing effects when administered therapeutically.
Key pharmacological property
BPC-157 is primarily an angiogenic modulator. It stimulates the formation of new blood vessels (angiogenesis) by upregulating Vascular Endothelial Growth Factor (VEGF) and modulating nitric oxide (NO) pathways. This increased blood supply is critical for healing relatively avascular tissues like tendons and ligaments[^4, ^6].
Outcome: Accelerated healing of transected or damaged soft tissues[^2, ^3].
Mechanism: Promotes fibroblast migration (via FAK-paxillin pathway) and collagen production while increasing blood flow to the injured area. It also enhances growth hormone receptor expression in tendon fibroblasts[1].
Evidence:Robust in animals. Multiple rat studies show BPC-157 significantly improves the tensile strength of healed Achilles tendons and medial collateral ligaments (MCL) after injury, promoting wound healing and tissue regeneration[^3, ^4, ^7].
Human Data: Limited to anecdotal reports and retrospective case series showing reduced pain and improved function in knee injuries. A systematic review highlights the emerging use in orthopaedic sports medicine, but notes the lack of high-quality human studies[2].
Evidence:Promising. Animal studies show complete healing of complex fistulas (rectovaginal, colocutaneous) and protection against alcohol/NSAID damage. Human Phase II trials for ulcerative colitis suggested safety and efficacy, but full results were not widely published in peer-reviewed journals.
Outcome: Nerve regeneration and protection against neurotoxins.
Mechanism: Modulates serotonin and dopamine systems; reduces neuroinflammation.
Evidence:Experimental. Rat studies demonstrate improved healing of transected sciatic nerves and reduced brain damage after traumatic brain injury (TBI), but no human data exists.
The primary driver of BPC-157's healing capability is its ability to stimulate VEGF (Vascular Endothelial Growth Factor) and its receptor VEGFR2. This triggers the growth of new blood vessels (angiogenesis), bringing oxygen and nutrients to damaged tissues that typically have poor blood supply, such as tendons and ligaments. It also enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro[^4, ^6, ^7].
BPC-157 interacts with the nitric oxide system in a unique "balancing" manner. It stimulates eNOS (endothelial Nitric Oxide Synthase) to produce nitric oxide for vasodilation but can also counteract the effects of excessive NO. This dual action helps maintain optimal blood flow without causing oxidative stress. It has modulatory effects on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway[3].
It activates Focal Adhesion Kinase (FAK) and paxillin, proteins essential for cell migration. This allows fibroblasts (the cells that build tissue structural framework) to move efficiently to the site of an injury and begin laying down new collagen[4].
BPC-157 upregulates EGR-1 (Early Growth Response 1) and its repressor NAB2. EGR-1 is a "master switch" gene that triggers the early wound healing response, while NAB2 ensures this response doesn't spiral out of control, preventing excessive scar tissue formation.
Subcutaneous (SubQ) Injection: The most common route for musculoskeletal injuries. While BPC-157 has systemic effects, many users prefer injecting locally (near the injury site) under the theory that local concentration aids healing, though evidence suggests systemic injection (into belly fat) is also effective.
Oral:
Acetate Salt: Standard form. Can be taken orally but may have reduced bioavailability compared to injection.
Arginate Salt (BPC-157 Stable): A modified form bound to L-arginine. This form is significantly more stable in gastric acid (pH 3.0) and is the preferred choice for treating gut issues (IBD, ulcers, GERD) via oral administration.
Intramuscular (IM): Less common; usually unnecessary given SubQ efficacy.
Some user protocols suggest a higher dose (e.g., 750–1000 mcg/day) for the first week ("loading phase") followed by a maintenance dose of 250 mcg/day, though there is no clinical evidence supporting the necessity of loading.
In the limited human studies available, BPC-157 has been described as well-tolerated.
Common: Injection site pain/redness (mild).
Anecdotal: Some users report nausea, headaches, or dizziness, particularly with oral use.
Rare/Theoretical: Potential for "anhedonia" (reduced pleasure response) has been discussed in online communities, possibly linked to its modulation of the dopaminergic system, but this is not documented in clinical literature.
Tumor Promotion: Because BPC-157 works by promoting angiogenesis (new blood vessel growth), there is a theoretical risk that it could accelerate the growth of existing tumors or precancerous lesions, which rely on blood supply to expand. While some studies suggest it may counteract tumor cachexia, no long-term carcinogenicity studies have been conducted to rule out this risk.
Immunogenicity: The FDA has cited the potential for peptides to provoke an immune response (antibody formation), which could lead to allergic reactions or reduced efficacy over time.
Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. 2020. https://pubmed.ncbi.nlm.nih.gov/33051481/↩︎
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. 2019. https://pubmed.ncbi.nlm.nih.gov/30915550/↩︎